|
US6472147B1
(en)
*
|
1999-05-25 |
2002-10-29 |
The Scripps Research Institute |
Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
|
|
WO2001023619A1
(en)
|
1999-09-29 |
2001-04-05 |
Xenoport, Inc. |
Compounds displayed on replicable genetic packages and methods of using same
|
|
US7037706B1
(en)
|
1999-09-29 |
2006-05-02 |
Xenoport, Inc. |
Compounds displayed on replicable genetic packages and methods of using same
|
|
CA2406236C
(en)
*
|
2000-04-17 |
2013-02-19 |
Dyax Corp. |
Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
|
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
|
DE60144063D1
(de)
|
2000-12-18 |
2011-03-31 |
Dyax Corp |
Gerichtete bibliotheken die genetisch verpackt sind
|
|
AU2002258602A1
(en)
|
2001-03-21 |
2002-10-08 |
Xenoport, Inc. |
Compounds displayed on icosahedral phage and methods of using same
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
US7202045B2
(en)
*
|
2001-09-19 |
2007-04-10 |
Regents Of The University Of Michigan |
Detection and treatment of cancers of the lung
|
|
US7175983B2
(en)
*
|
2001-11-02 |
2007-02-13 |
Abmaxis, Inc. |
Adapter-directed display systems
|
|
AU2003253193B2
(en)
*
|
2002-07-30 |
2009-07-02 |
Morphosys Ag |
Novel tricistronic vectors and uses therefor
|
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
|
PT1558643E
(pt)
|
2002-11-09 |
2009-08-24 |
Immunocore Ltd |
Apresentação de um receptor das células t
|
|
EP2290107A1
(en)
|
2003-01-07 |
2011-03-02 |
Dyax Corporation |
Kunitz domain library
|
|
US9200061B2
(en)
|
2004-02-06 |
2015-12-01 |
Morpho Sys AG |
Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
|
|
CA2555185C
(en)
|
2004-02-06 |
2020-03-24 |
Morphosys Ag |
Anti-cd38 human antibodies and uses therefor
|
|
JP2008504013A
(ja)
|
2004-02-06 |
2008-02-14 |
モルフォシス・アクチェンゲゼルシャフト |
抗ｃｄ３８ヒト抗体及びその用途
|
|
WO2006095345A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Ramot At Tel-Aviv University Ltd. |
Targeted drug-carrying bacteriophages
|
|
BRPI0610796B8
(pt)
|
2005-05-18 |
2021-05-25 |
Morphosys Ag |
anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo
|
|
US8114964B2
(en)
|
2005-05-19 |
2012-02-14 |
Centocor, Inc. |
Anti-MCP-1 antibodies, compositions, methods and uses
|
|
AR053489A1
(es)
|
2005-05-24 |
2007-05-09 |
Morphosys Ag |
Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano
|
|
JP5362359B2
(ja)
|
2005-10-12 |
2013-12-11 |
モルフォシス アーゲー |
ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング
|
|
BRPI0520677A2
(pt)
|
2005-11-09 |
2009-05-19 |
Bayer Schering Pharma Ag |
identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina
|
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
|
AU2006350452B2
(en)
*
|
2005-12-20 |
2012-10-25 |
Morphosys Ag |
Novel collection of HCDR3 regions and uses therefor
|
|
TW200815470A
(en)
|
2006-03-30 |
2008-04-01 |
Novartis Ag |
Compositions and methods of use for antibodies of c-Met
|
|
EP2420832A1
(en)
|
2006-05-04 |
2012-02-22 |
Abmaxis, Inc. |
Cross-species and multi-species display systems
|
|
DK2046951T5
(da)
|
2006-07-05 |
2012-01-23 |
Catalyst Biosciences Inc |
Proteasesreeningsmetoder og proteaser identificeret dermed
|
|
AU2007331484B2
(en)
|
2006-12-12 |
2012-11-15 |
Morphosys Ag |
Internalization
|
|
KR20100089816A
(ko)
*
|
2007-08-21 |
2010-08-12 |
모르포시스 아게 |
이황화 결합을 형성하기 위한 개선된 방법
|
|
BRPI0816094A2
(pt)
|
2007-08-30 |
2015-03-03 |
Daiichi Sankyo Co Ltd |
Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
|
|
CA2697193C
(en)
|
2007-09-14 |
2017-06-06 |
Adimab, Inc. |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
TWI489993B
(zh)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
|
|
CN104151429B
(zh)
|
2007-11-26 |
2018-07-10 |
拜耳知识产权有限责任公司 |
抗-间皮素抗体及其用途
|
|
US8680022B2
(en)
*
|
2008-02-05 |
2014-03-25 |
Bicycle Therapeutics Limited |
Methods and compositions
|
|
US9873957B2
(en)
|
2008-03-13 |
2018-01-23 |
Dyax Corp. |
Libraries of genetic packages comprising novel HC CDR3 designs
|
|
US10485879B2
(en)
|
2008-04-15 |
2019-11-26 |
Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health |
Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues
|
|
JP5667043B2
(ja)
|
2008-04-15 |
2015-02-12 |
アメリカ合衆国ＧＯＶＥＲＮＭＥＮＴ ＯＦ ＴＨＥ ＵＮＩＴＥＤ ＳＴＡＴＥＳ ＯＦ ＡＭＥＲＩＣＡ， ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ＴＨＥ ＳＥＣＲＥＴＡＲＹ， ＤＥＰＡＲＴＭＥＮＴ ＯＦ ＨＥＡＬＴＨＡＮＤ ＨＵＭＡＮ ＳＥＲＶＩＣＥＳ |
阻害性オリゴヌクレオチドを送達するための組成物および方法
|
|
CA3049612C
(en)
|
2008-04-24 |
2023-01-10 |
Dyax Corp. |
Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
|
|
WO2010015608A1
(en)
|
2008-08-05 |
2010-02-11 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
|
CA3059768A1
(en)
|
2008-09-05 |
2010-03-11 |
President And Fellows Of Harvard College |
Continuous directed evolution of proteins and nucleic acids
|
|
WO2010079189A1
(en)
|
2009-01-09 |
2010-07-15 |
Morphosys Ag |
Display vectors and methods and uses thereof
|
|
TWI480050B
(zh)
|
2009-02-10 |
2015-04-11 |
Daiichi Sankyo Co Ltd |
抗－ｍｓｔ１ｒ抗體及其用途
|
|
BRPI1016055A2
(pt)
|
2009-04-27 |
2016-05-10 |
Novartis Ag |
composição e métodos de uso para anticorpos terapêuticos específicos para a subunidade beta i do receptor de il-12
|
|
NO2424895T3
(enExample)
|
2009-04-27 |
2018-02-03 |
|
|
|
UY32560A
(es)
|
2009-04-29 |
2010-11-30 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
|
US20120263743A1
(en)
*
|
2009-04-30 |
2012-10-18 |
Cytos Biotechnology Ag |
Influenza hemagglutinin compositions and uses thereof
|
|
NZ596603A
(en)
|
2009-05-29 |
2013-07-26 |
Morphosys Ag |
A collection of antibodies or fragments having properties relevant to developability
|
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
|
US20110082054A1
(en)
*
|
2009-09-14 |
2011-04-07 |
Dyax Corp. |
Libraries of genetic packages comprising novel hc cdr3 designs
|
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
|
CA2781019A1
(en)
|
2009-11-17 |
2011-05-26 |
Janssen Biotech, Inc. |
Display of disulfide linked dimeric proteins on filamentous phage
|
|
CN102770555B
(zh)
|
2009-11-17 |
2015-01-28 |
詹森生物科技公司 |
改善的细菌膜蛋白分泌
|
|
EP2528944B1
(en)
|
2010-01-29 |
2015-08-12 |
MorphoSys AG |
Rodent combinatorial antibody libraries
|
|
US9290573B2
(en)
|
2010-05-06 |
2016-03-22 |
Novartis Ag |
Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
|
|
ES2659406T3
(es)
|
2010-05-06 |
2018-03-15 |
Novartis Ag |
Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
|
|
WO2012009568A2
(en)
|
2010-07-16 |
2012-01-19 |
Adimab, Llc |
Antibody libraries
|
|
PL2606070T3
(pl)
|
2010-08-20 |
2017-06-30 |
Novartis Ag |
Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
KR20130066682A
(ko)
|
2010-10-05 |
2013-06-20 |
다이이찌 산쿄 가부시키가이샤 |
항체 표적 파골세포－관련 단백질 ｓｉｇｌｅｃ－１５
|
|
DK2640742T3
(en)
|
2010-11-19 |
2018-12-03 |
Morphosys Ag |
COLLECTION OF ANTIBODY SEQUENCES AND THEIR APPLICATIONS
|
|
JP6088438B2
(ja)
|
2010-12-22 |
2017-03-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
連続的定向進化
|
|
WO2013010955A1
(en)
|
2011-07-15 |
2013-01-24 |
Morphosys Ag |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
|
|
HUE037087T2
(hu)
|
2011-10-19 |
2018-08-28 |
Morphosys Ag |
IL17C antagonistái gyulladásos rendellenességek kezelésére
|
|
EP2788382A2
(en)
|
2011-12-05 |
2014-10-15 |
Novartis AG |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
|
AU2012349735B2
(en)
|
2011-12-05 |
2016-05-19 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
JP2015508638A
(ja)
|
2012-02-03 |
2015-03-23 |
ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ |
ファージディスプレイを用いてペプチド誘導体ライブラリーを定量化するための方法
|
|
EP3508497A1
(en)
|
2012-05-24 |
2019-07-10 |
Mountgate Group Limited |
Compositions and methods related to prevention and treatment of rabies infection
|
|
WO2014026905A1
(en)
|
2012-08-17 |
2014-02-20 |
Morphosys Ag |
Complex-specific antibodies and antibody fragments and its use
|
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
|
AU2013343099A1
(en)
|
2012-11-09 |
2015-05-14 |
Pfizer Inc. |
Platelet-derived growth factor B specific antibodies and compositions and uses thereof
|
|
US9428577B2
(en)
|
2012-11-09 |
2016-08-30 |
Pfizer Inc. |
Platelet-derived growth factor B specific antibodies and compositions and uses thereof
|
|
WO2014096333A1
(en)
|
2012-12-20 |
2014-06-26 |
Morphosys Ag |
Anti-staphylococcal antibodies
|
|
WO2014159239A2
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Antibodies against notch 3
|
|
MX366978B
(es)
|
2013-03-15 |
2019-08-01 |
Novartis Ag |
Conjugados de anticuerpo - farmaco.
|
|
SG11201507871XA
(en)
|
2013-04-12 |
2015-10-29 |
Morphosys Ag |
Antibodies targeting m-csf
|
|
EP2986642A1
(en)
|
2013-04-17 |
2016-02-24 |
MorphoSys AG |
Antibodies targeting specifically human cxcr2
|
|
HRP20201906T1
(hr)
|
2013-12-20 |
2021-04-02 |
Fred Hutchinson Cancer Research Center |
Označene kimerne efektorske molekule i njihovi receptori
|
|
WO2015134121A2
(en)
|
2014-01-20 |
2015-09-11 |
President And Fellows Of Harvard College |
Negative selection and stringency modulation in continuous evolution systems
|
|
BR112016021004A2
(pt)
|
2014-03-14 |
2018-01-23 |
Immunocore Limited |
biblioteca de partículas; receptor de células t (tcr) isolado não natural; uso de uma biblioteca; método de obtenção de um receptor de células t que se liga especificamente a um antígeno de peptídeo; ácido nucleico; método de construção de uma biblioteca de partículas; método de obtenção de um receptor de células t que se liga especificamente a um antígeno de peptídeo; e partícula
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
WO2016077052A2
(en)
|
2014-10-22 |
2016-05-19 |
President And Fellows Of Harvard College |
Evolution of proteases
|
|
PE20170912A1
(es)
|
2014-11-14 |
2017-07-12 |
Novartis Ag |
Conjugados de anticuerpo-farmaco
|
|
EP3273994B1
(en)
|
2015-03-27 |
2021-12-01 |
University of Southern California |
Car t-cell therapy directed to lhr for the treatment of solid tumors
|
|
US11299729B2
(en)
|
2015-04-17 |
2022-04-12 |
President And Fellows Of Harvard College |
Vector-based mutagenesis system
|
|
WO2016176652A2
(en)
|
2015-04-29 |
2016-11-03 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
|
JP6985934B2
(ja)
*
|
2015-04-29 |
2021-12-22 |
フレッド ハッチンソン キャンサー リサーチ センター |
操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用
|
|
EP3095465A1
(en)
|
2015-05-19 |
2016-11-23 |
U3 Pharma GmbH |
Combination of fgfr4-inhibitor and bile acid sequestrant
|
|
CN107847601A
(zh)
|
2015-06-04 |
2018-03-27 |
南加利福尼亚大学 |
Lym‑1和lym‑2靶向的car细胞免疫疗法
|
|
CA2982237A1
(en)
|
2015-06-05 |
2016-12-08 |
Novartis Ag |
Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
|
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
|
WO2017015545A1
(en)
|
2015-07-22 |
2017-01-26 |
President And Fellows Of Harvard College |
Evolution of site-specific recombinases
|
|
US11524983B2
(en)
|
2015-07-23 |
2022-12-13 |
President And Fellows Of Harvard College |
Evolution of Bt toxins
|
|
WO2017019895A1
(en)
|
2015-07-30 |
2017-02-02 |
President And Fellows Of Harvard College |
Evolution of talens
|
|
RS61763B1
(sr)
|
2015-09-09 |
2021-05-31 |
Novartis Ag |
Antitela koja vezuju timusni stromalni limfopoetin (tslp) i metode za korišćenje antitela
|
|
MY186352A
(en)
|
2015-09-09 |
2021-07-15 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
|
|
GB201516277D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR libraries
|
|
GB201516265D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
|
GB201516272D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
|
GB201516269D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
|
GB201516274D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
|
GB201516275D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
|
GB201516270D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
|
JP7054924B2
(ja)
|
2015-09-23 |
2022-04-15 |
サイトイミューン セラピューティクス， インコーポレイテッド |
免疫療法のためのｆｌｔ３指向ｃａｒ細胞
|
|
US12043852B2
(en)
|
2015-10-23 |
2024-07-23 |
President And Fellows Of Harvard College |
Evolved Cas9 proteins for gene editing
|
|
SG11201805941WA
(en)
|
2016-02-17 |
2018-09-27 |
Novartis Ag |
Tgfbeta 2 antibodies
|
|
ES2877376T3
(es)
|
2016-02-19 |
2021-11-16 |
Morphosys Ag |
Anticuerpos para IL-17C
|
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
|
US11254734B2
(en)
|
2016-11-14 |
2022-02-22 |
Morphosys Ag |
Fab molecules with a rodent hinge region and a non-rodent CH1 region
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
WO2019010164A1
(en)
|
2017-07-06 |
2019-01-10 |
President And Fellows Of Harvard College |
Evolution of trna synthetases
|
|
EP3444275A1
(en)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoclonal antibody anti-fgfr4
|
|
US12060553B2
(en)
|
2017-08-25 |
2024-08-13 |
President And Fellows Of Harvard College |
Evolution of BoNT peptidases
|
|
WO2019056002A1
(en)
|
2017-09-18 |
2019-03-21 |
President And Fellows Of Harvard College |
CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
|
|
AU2018364630A1
(en)
|
2017-11-09 |
2020-05-21 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
|
WO2019102353A1
(en)
|
2017-11-22 |
2019-05-31 |
Novartis Ag |
Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
|
|
US11453883B2
(en)
|
2018-04-05 |
2022-09-27 |
Bio-Rad Abd Serotec Gmbh |
Display systems for proteins of interest
|
|
EP3793596A1
(en)
|
2018-05-16 |
2021-03-24 |
MorphoSys AG |
Antibodies targeting glycoprotein vi
|
|
WO2019241649A1
(en)
|
2018-06-14 |
2019-12-19 |
President And Fellows Of Harvard College |
Evolution of cytidine deaminases
|
|
US12129298B2
(en)
|
2018-06-21 |
2024-10-29 |
Daiichi Sankyo Company, Limited |
Compositions including CD3 antigen binding fragments and uses thereof
|
|
EP3827116A4
(en)
|
2018-07-23 |
2022-05-11 |
The Governors of the University of Alberta |
Genetically-encoded bicyclic peptide libraries
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
KR20210152472A
(ko)
|
2019-03-11 |
2021-12-15 |
메모리얼 슬로안 케터링 캔서 센터 |
Cd22 항체 및 이를 사용하는 방법
|
|
JP7617012B2
(ja)
|
2019-03-14 |
2025-01-17 |
モルフォシス・アーゲー |
Ｃ５ａＲを標的とする抗体
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
PH12023550015A1
(en)
|
2020-07-16 |
2024-03-11 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
|
AU2021350342A1
(en)
|
2020-09-24 |
2023-03-09 |
Morphosys Ag |
Novel human antibodies binding to human CD3 epsilon
|
|
CA3204628A1
(en)
|
2021-01-13 |
2022-07-21 |
John T. POIRIER |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
US20240115721A1
(en)
|
2021-01-13 |
2024-04-11 |
Memorial Sloan Kettering Cancer Center |
Anti-dll3 antibody-drug conjugate
|
|
US20240391996A1
(en)
|
2021-08-31 |
2024-11-28 |
Taisho Pharmaceutical Co., Ltd. |
Anti-growth hormone antibody
|
|
AU2023240297A1
(en)
|
2022-03-22 |
2024-10-03 |
Morphosys Ag |
Deimmunized antibodies specific for cd3
|
|
GB202204159D0
(en)
|
2022-03-24 |
2022-05-11 |
Heptares Therapeutics Ltd |
Antibodies
|
|
WO2024236163A1
(en)
|
2023-05-17 |
2024-11-21 |
Morphosys Ag |
T cell receptor beta constant region 2 (trbc2) antibodies
|
|
WO2025003511A1
(en)
|
2023-06-30 |
2025-01-02 |
Morphosys Ag |
Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
|
|
WO2025082777A1
(en)
|
2023-10-17 |
2025-04-24 |
Morphosys Ag |
Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
|